1. Home
  2. ALLO vs MRNO Comparison

ALLO vs MRNO Comparison

Compare ALLO & MRNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • MRNO
  • Stock Information
  • Founded
  • ALLO 2017
  • MRNO 2021
  • Country
  • ALLO United States
  • MRNO United Kingdom
  • Employees
  • ALLO N/A
  • MRNO N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • MRNO
  • Sector
  • ALLO Health Care
  • MRNO
  • Exchange
  • ALLO Nasdaq
  • MRNO NYSE
  • Market Cap
  • ALLO 677.5M
  • MRNO 794.8M
  • IPO Year
  • ALLO 2018
  • MRNO N/A
  • Fundamental
  • Price
  • ALLO $2.27
  • MRNO $8.87
  • Analyst Decision
  • ALLO Buy
  • MRNO
  • Analyst Count
  • ALLO 12
  • MRNO 0
  • Target Price
  • ALLO $10.06
  • MRNO N/A
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • MRNO 4.5K
  • Earning Date
  • ALLO 11-07-2024
  • MRNO 11-26-2024
  • Dividend Yield
  • ALLO N/A
  • MRNO N/A
  • EPS Growth
  • ALLO N/A
  • MRNO N/A
  • EPS
  • ALLO N/A
  • MRNO N/A
  • Revenue
  • ALLO $43,000.00
  • MRNO $24,458,160.00
  • Revenue This Year
  • ALLO N/A
  • MRNO N/A
  • Revenue Next Year
  • ALLO $5,902.96
  • MRNO N/A
  • P/E Ratio
  • ALLO N/A
  • MRNO N/A
  • Revenue Growth
  • ALLO 26.47
  • MRNO 296.23
  • 52 Week Low
  • ALLO $2.01
  • MRNO $3.60
  • 52 Week High
  • ALLO $5.78
  • MRNO $38.00
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.00
  • MRNO 49.65
  • Support Level
  • ALLO $2.95
  • MRNO $8.97
  • Resistance Level
  • ALLO $3.36
  • MRNO $10.85
  • Average True Range (ATR)
  • ALLO 0.26
  • MRNO 0.97
  • MACD
  • ALLO -0.06
  • MRNO -0.01
  • Stochastic Oscillator
  • ALLO 0.91
  • MRNO 52.80

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About MRNO MURANO GLOBAL INVESTMENTS LIMITED

Murano Global Investments PLC is a real estate company that owns, develops, and invests in hotel, resort, and commercial properties throughout Mexico. Its portfolio includes the Andaz and Mondrian Hotels in Mexico City and Vivid Hotel Grand Island. The revenues are derived from the products and services provided to our customers such as Room rentals, Food and beverage, Private events, Spa services, and Other services.

Share on Social Networks: